Showing results (231-240 of 258) with videos related to
Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 TherapyMatthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 8, 2019
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II StudyAnish Thomas, Rasa Vilimas, Christopher Trindade, et al.Proceedings of the National Academy of Sciences of the United States of America|July 7, 2011
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cellsJohanny Tonos De Leon, Aki Iwai, Clementine Feau, et al.The Lancet. Oncology|January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan, Corey A Carter, Arlene Berman, et al.Oncoimmunology|September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancerLauren V Wood, Antonio Fojo, Brenda D Roberson, et al.Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.European Journal of Cancer (Oxford, England : 1990)|December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesShivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.Pageof 26